Table 1-.
Characteristics of the studies included
| Krishnan, Giralt | Gahrton, Bjorkstrand | Giacone, Bruno | Rosinol | Total | |
|---|---|---|---|---|---|
| BMT CTN | EBMT | Torino | GEM-PETHEMA | ||
| Population | Newly diagnosed MM patients | Newly diagnosed MM patients | Newly diagnosed MM patients | Not achieving CR/nCR after first autologous | |
| Years of accrual | 2003–2007 | 2001 to 2005 | 1998–2004 | 1999–2004 | |
| Number of participants | 709 | 357 | 162 | 110 | 1,338 |
| Auto-auto | 483 | 249 | 82 | 85 | 899 |
| Auto-allo | 226 | 108 | 80 | 25 | 439 |
| Median follow up (mo) | 75.5 | 75.5 | 57.6 | 87.7 | 75.3 |
| Median follow up of survivors (mo) | 122.6 | 94.2 | 146.9 | 140.1 | 118.5 |
| Age criteria | ≤70 | <70 | ≤65 | <65 | |
| Male patients | 418 (59%) | 211 (59%) | 88 (54%) | 59 (54%) | 776 (58%) |
| Median age (years) | |||||
| Auto-auto | 55 | 57 | 55 | 55 | 56 |
| Auto-allo | 52 | 54 | 55 | 52 | 53 |
| Age ≥ 60 years | |||||
| Auto-auto | 133 (28%) | 81 (33%) | 18 (22%) | 30 (35%) | 262 (29%) |
| Auto-allo | 32 (14%) | 18 (17%) | 15 (19%) | 3 (12%) | 68 (15%) |
| Conditioning regimen | |||||
| Auto-auto | Mel200 | Mel200 | Mel200, Mel100– 200 | Mel200 or CVB | |
| Auto-allo | TBI 200cGy | Flu+TBI 200cGy | TBI 200cGy | Flu+Mel | |
| GVHD prophylaxis | CSA + MMF | CSA + MMF | CSA + MMF | CSA + MTX |
HR= high risk, Mel200= Melphalan 200 mg/m2, TBI = total body irradiation; CSA = Cyclosporine A; MMF = Mycophenolate mofetil; MTX = Methotrexate. Bu= Busulfan; Flu= Fludarabine; ATG= Anti-thymocyte globulin; CVB = Cyclophosphamide, etoposide, BCNU.